CS585
Cardiovascular Disease (potential: Thrombosis prevention without bleeding risk, Pulmonary Hypertension)
Key Facts
About Cereno Scientific
Cereno Scientific is a Swedish clinical-stage biotech company developing first-in-class epigenetic therapies targeting the root causes of rare cardiovascular and pulmonary diseases. The company's lead program, CS1, has demonstrated disease-modifying potential in a Phase IIa trial for PAH and holds FDA Fast Track designation, while its broader HDACi portfolio and preclinical prostacyclin receptor agonist CS585 address significant unmet medical needs. With a strengthened focus on rare diseases, Cereno aims to deliver high treatment value through a business model characterized by relatively shorter development timelines and reduced capital requirements.
View full company profile